MARKET WIREYahoo Finance • 16h ago
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
Why PRTA Stock dropped -4.62% Today — RQD Quant Desk Flash
$8.47 -4.62% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.38
Prothena Corporation plc (PRTA) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $434.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PRTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $8.47 (-4.62% 1D, market cap $434.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #945 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PRTA compare to BLSM and CRMD in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PRTA?
▼
Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.38 (-1.02%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRTA)Realized 20D OHLCV Swing Band: ±11%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY PRTA SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)
FRED Regime × Technicals: 18% of 52W Range • RSI-14 at 48.3 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (26% of score)
20D Institutional Volume Accumulation (±11% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$8.36+1.7% Next Q
15
Q2 (-2Q)Grade E$8.50+3.6% Next Q
18
Q3 (-1Q)Grade E$8.81-3.9% Next Q
20
CurrentGrade E$8.47-11.1% Hist 90D α
23
Trajectory: E (15) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PRTA Turnaround Squeeze
While PRTA currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.73) and Max Pain ($8.89) forces dealer call-delta covering toward $12.39.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PRTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PRTA Stock dropped -4.62% Today — RQD Quant Desk Flash
Prothena Corporation plc (PRTA) dropped -4.62% to $8.47, trading at 18% of its 52-week range ($7.73 – $11.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 18% of its 52-week range ($7.73 – $11.8) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11% around $8.47 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live PRTA Headlines & Catalysts
MARKET WIREwww.marketscreener.com • 19h ago
Prothena to Report Third Quarter 2026 Financial Results on November 5www.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 22h ago
Prothena's Partnership Strategy: Growth Driver or Limitation?Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
PRTA Q3'26 Earnings: EPS estimate is (0.23) USDTradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
(PRTA) and the Role of Price-Sensitive AllocationsStock Traders Daily report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Aspen Neuroscience (ASPE) Stock Price, News & AnalysisStock Titan report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREwww.marketscreener.com • 1d ago
Prothena Corporation Public Limited Company Terminates PRX019 Global License Agreement With Bristol Myers Squibbwww.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
CLYM Stock Price and Chart — NASDAQ:CLYMTradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 13d ago
How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug CompetitionNovo Nordisk is pressing ahead with obesity and cardiometabolic drug development, including CagriSema regulatory submissions and a partnership with Prothena on Coramitug, while also running a DKK 15b share buyback that h
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRTA)
- ✓Walkthrough of PRTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PRTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.50%▼ DESCENDING CHANNEL
2026-11-03O $8.88H $8.88L $8.47C $8.47VOL 452.3K
RES: $9.21SUP: $7.71SMA50: $8.73SMA200: $9.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PRTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PRTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PRTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PRTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRTA)
Health Care Rank #945 of 1016
⚔️ BLSM vs PRTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PRTA vs. BLSM, CRMD, KMDA, ASMB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Prothena Corporation plc (PRTA) ranks #945 by composite RQD confidence (23/100, grade E) and #465 by equity capitalization ($434.8M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while CRMD leads on capital efficiency and profitability with 45.5% ROIC and 88.5% gross margin. CRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PRTA at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PRTA
ACTIVE
Prothena Corporation plc | E | 23/100 | — | — | -35.0% | -4.62% | $434.8M | Benchmark Subject |
| BLSM BlossomHill Therapeutics Inc. | D- | 42/100 | — | — | — | -9.60% | $437.0M | /blsm-vs-prta → |
| CRMD CorMedix Inc. | C- | 59/100 | 3.7x | 88.5% | 45.5% | -25.46% | $443.9M | /crmd-vs-prta → |
| KMDA Kamada Ltd. | D | 46/100 | — | — | — | -3.14% | $444.4M | /kmda-vs-prta → |
| ASMB Assembly Biosciences Inc. | E | 16/100 | — | — | -6.5% | -3.50% | $409.9M | /asmb-vs-prta → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001559053In its most recent audited fiscal period (FY2025, filed 2025-12-31), Prothena Corporation plc (PRTA) reported GAAP revenue of $9.7M (-92.8% vs. FY2024 revenue of $135.2M , and -89.4% cumulative change since FY2023) , GAAP net income of -$244.1M, operating cash flow of -$163.6M, and free cash flow of -$163.6M (-9.0% YoY). On the balance sheet, PRTA closed FY2025 with $326.8M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.7M | -$244.1M | -$163.6M | -$163.6M | $326.8M | — |
| FY2024 (FY) | 2024-12-31 | $135.2M | -$122.3M | -$150.1M | -$150.1M | $547.1M | — |
| FY2023 (FY) | 2023-12-31 | $91.4M | -$147.0M | -$133.9M | -$133.9M | — | — |
3. PRTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PRTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Prothena Corporation plc (NASDAQ: PRTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $8.47 (-4.62% 1D, market cap $434.8M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PRTA ranks #945 in composite RQD confidence.
How does PRTA compare to BLSM and CRMD in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PRTA carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BLSM (BlossomHill Therapeutics Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC —, cap $437.0M) and CRMD (CorMedix Inc.) posts a C- grade (59/100 RQD, P/E 3.7x, ROIC 45.5%, cap $443.9M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while CRMD leads on capital efficiency (45.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PRTA?
Per PRTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001559053), Prothena Corporation plc generated $9.7M in revenue (-92.8% YoY), -$244.1M in net income, and -$163.6M in free cash flow against $326.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PRTA trading relative to its 50-day, 200-day, and 52-week technical levels?
PRTA last traded at $8.47 (-4.62% on volume of 452,343 shares), positioning the stock -2.98% below its 50-day simple moving average ($8.73) and -8.23% below its 200-day simple moving average ($9.23). Across its 52-week range of $7.73 to $11.80, PRTA sits at the 18.2% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($7.54 to $9.40).
PRTA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PRTA stock moving today?
Why PRTA Stock dropped -4.62% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 23/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PRTA — Prothena Corporation plc: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:16Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PRTA scores 26 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 5 out of 20, reflecting ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the business is not currently generating returns on capital or free cash flow, so any valuation case must rest on future cash generation rather than present earnings. The Whale 13F Flow pillar scores 9 out of 20, indicating institutional accumulation and options positioning that are weaker than the top of the scale. The Insider Conviction pillar scores 3 out of 20 on SEC Form 4 and Congressional PTR cluster flow, the lowest of the five pillars, which signals limited insider-side confidence in the source data. The Macro Regime Fit pillar scores 7 out of 20, with a beta of 1.0 and sector sensitivity that offers no defensive cushion. The Forensic Balance Sheet pillar scores 2 out of 20, with an Altman Z of 0.2, a Piotroski F of 2 out of 9, and Debt/Equity of 0.5, placing financial-distress risk at the center of the thesis. Taken together, the upside drivers are limited to a cash balance and a potential recovery in operating trajectory, while the tradeoffs are negative operating margins, distress-range forensic scores, and a rating that flags avoidance.
Business
Per the profile, Prothena Corporation plc is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, with a market capitalization of $0.5B. The source data does not describe specific products, customers, or revenue mechanics. Per the SEC financials, reported revenue was $9.7M in FY 2025, $135.2M in FY 2024, and $91.4M in FY 2023, indicating material year-to-year variation. Not available in source data for further detail on how the company monetizes its activities.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $9.7M | $-214.6M | $-244.1M | N/A | $-163.6M | $307.5M | N/A |
| FY 2024 | $135.2M | $-154.6M | $-122.3M | N/A | $-150.1M | $471.4M | N/A |
| FY 2023 | $91.4M | $-191.0M | $-147.0M | N/A | $-133.9M | N/A | N/A |
Per the market data, operating margin and net margin are both -60%, and gross margin is 0%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 0.2, with a Piotroski F-Score of 2 out of 9 and Debt/Equity of 0.5. Cash declined from $471.4M in FY 2024 to $307.5M in FY 2025 while free cash flow remained negative in each reported period. Debt figures are not available in source data for any period.
Recent Catalysts & News Wire Analysis
- Earnings event: Prothena plans to report third quarter 2026 financial results on November 5 (MARKET WIRE, marketscreener.com).
- EPS expectation: A TradingView report references a Q3'26 EPS estimate of (0.23) USD (MARKET WIRE).
- Partnership strategy: A Yahoo Finance headline questions whether the partnership strategy is a growth driver or a limitation, flagged as a CATALYST with a GREEN light.
- Value-comparison coverage: A Yahoo Finance piece compares PRTA against CRMD for value investors (MARKET WIRE).
- Allocation commentary: A Stock Traders Daily piece addresses price-sensitive allocations involving PRTA (MARKET WIRE).
- Risk watch item: A Stock Titan page for Aspen Neuroscience (ASPE) is tagged to PRTA; its relevance to Prothena is not explained in source data.
- Proprietary signals: Not available in source data; the Butterfly graph contains no proprietary signals.
Open Questions
- What are PRTA's specific products, clinical or commercial pipeline, and revenue sources that explain the swing from $135.2M in FY 2024 to $9.7M in FY 2025?
- What is the debt position, since debt is reported as N/A in every period while Debt/Equity is cited at 0.5?
- What is the cash runway implied by $307.5M of cash against FY 2025 free cash flow of $-163.6M?
- What is the basis and timing of the partnership strategy referenced in news coverage, and how would it affect revenue?
- Which analyst estimates, price targets, and institutional or insider holders exist, given that those source sections are empty?
PRTA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Prothena Corporation plc (PRTA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 16h ago
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now? Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 19h ago
Prothena to Report Third Quarter 2026 Financial Results on November 5 www.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 22h ago
Prothena's Partnership Strategy: Growth Driver or Limitation? Yahoo Finance report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
PRTA Q3'26 Earnings: EPS estimate is (0.23) USD TradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
(PRTA) and the Role of Price-Sensitive Allocations Stock Traders Daily report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Aspen Neuroscience (ASPE) Stock Price, News & Analysis Stock Titan report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE www.marketscreener.com • 1d ago
Prothena Corporation Public Limited Company Terminates PRX019 Global License Agreement With Bristol Myers Squibb www.marketscreener.com report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
CLYM Stock Price and Chart — NASDAQ:CLYM TradingView report covering Prothena Corporation plc (PRTA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PRTA Bull vs. Bear Conversation Board — What's Your Call at $8.47?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRTA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $7.81 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PRTA (E • RQD 26/100) a Buy at $8.88?
Welcome to the PRTA (Prothena Corporation plc) Roar Pit. Current RQD Composite is 26/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $7.19 (-19.0%)
Spot @ $8.88 Pump the brakes on PRTA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PRTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Prothena Corporation plc expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
CA CashFlowKing Verified K Arena Trader 🐂 BULLISH
🎯 Target: $11.28 (+27.0%)
Spot @ $8.88 PRTA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PRTA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $8.88 (52-wk range $7.73 - $11.80), any beat on forward guidance forces shorts and underweight funds to chase.